These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11448730)

  • 1. Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
    Essey RJ; McDougall BR; Robinson WE
    Antiviral Res; 2001 Sep; 51(3):189-202. PubMed ID: 11448730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
    Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
    AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1.
    Beale KK; Robinson WE
    Antiviral Res; 2000 Jun; 46(3):223-32. PubMed ID: 10867160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
    Merrill DP; Moonis M; Chou TC; Hirsch MS
    J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
    Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
    J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
    Patick AK; Boritzki TJ; Bloom LA
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
    Xu W; Wang Q; Yu F; Lu L; Jiang S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.
    Tremblay C; Merrill DP; Chou TC; Hirsch MS
    J Acquir Immune Defic Syndr; 1999 Dec; 22(5):430-6. PubMed ID: 10961603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
    Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
    Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.